Free Trial
→ 2013 Bitcoin miner reveals his trading system (free) (From Crypto Swap Profits) (Ad)tc pixel

ImmuPharma (LON:IMM) Stock Price Down 12.7% - Here's Why

Written by MarketBeat
September 17, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's stock price fell by 12.7%, trading as low as GBX 14.10 ($0.19) compared to a previous closing price of GBX 17.60 ($0.24).
  • The company's market capitalization is £75.46 million, with an extremely high price-to-earnings ratio of -1,696.63, indicating significant negative earnings.
  • ImmuPharma reported a negative earnings per share (EPS) of GBX (0.38) for the last quarter and is expected to post an EPS of -339.0000022 for the current fiscal year.
  • Five stocks we like better than ImmuPharma.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded down 12.7% during mid-day trading on Tuesday . The company traded as low as GBX 14.10 ($0.19) and last traded at GBX 15.37 ($0.21). 24,661,160 shares changed hands during mid-day trading, an increase of 195% from the average session volume of 8,361,789 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Price Performance

The company has a market capitalization of £75.46 million, a price-to-earnings ratio of -1,696.63 and a beta of 1.53. The stock has a fifty day simple moving average of GBX 3.43 and a 200-day simple moving average of GBX 3.01.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.